First bioprosthesis thrombosis after transcatheter mitral valve-in-valve implantation: diagnosis and treatment.

J Am Coll Cardiol

Technische Universitaet Dresden, Heart Center, University Hospital, Department of Internal Medicine and Cardiology, Dresden, Germany.

Published: May 2014

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2013.11.067DOI Listing

Publication Analysis

Top Keywords

bioprosthesis thrombosis
4
thrombosis transcatheter
4
transcatheter mitral
4
mitral valve-in-valve
4
valve-in-valve implantation
4
implantation diagnosis
4
diagnosis treatment
4
bioprosthesis
1
transcatheter
1
mitral
1

Similar Publications

Background: The Edwards Sapien percutaneous valve (Edwards Lifesciences, Irvine, CA, USA) is a promising therapeutic option for congenital atrioventricular disease mostly because of the possibility to accommodate somatic growth with balloon dilatation.

Case Summary: This article reports the performance of the Edwards Sapien 3 valve in atrioventricular valve position in four paediatric patients.

Discussion: Despite aggressive antiplatelet and anticoagulation strategies, most patients showed early bioprosthesis dysfunction, with increasing gradient not related with somatic growth.

View Article and Find Full Text PDF

Objectives: Safety, efficacy, and durability are important considerations when selecting a bioprosthesis for aortic valve replacement (AVR). This study assessed 7-year clinical outcomes and haemodynamic performance of the Avalus bioprosthesis.

Methods: Patients indicated for surgical AVR were enrolled in this prospective, nonrandomized trial, conducted across 39 sites globally.

View Article and Find Full Text PDF
Article Synopsis
  • Bioprosthetic heart valves (BHVs) are commonly used in medicine but can suffer from fatigue damage due to their sensitivity to body positions.
  • The study analyzed the effects of different postures—upright, sitting, prone, supine, and orthostatic hypotension (OH)—on the performance of these valves using a simulation model.
  • Results indicated that the OH position negatively impacted valve function the most, causing increased regurgitation and flutter, which heightens the risk of thrombosis and damage; thus, patients should avoid this posture for better valve longevity.
View Article and Find Full Text PDF

Three-Year Outcomes Following TAVR in Younger (<75 Years) Low-Surgical-Risk Severe Aortic Stenosis Patients.

Circ Cardiovasc Interv

November 2024

Department of Interventional Cardiology and Cardiothoracic Surgery, Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, TX (N.S.K., M.J.R.).

Article Synopsis
  • A study compared transcatheter aortic valve replacement (TAVR) with traditional surgery in low-risk patients under 75 years old with severe aortic stenosis to evaluate safety and effectiveness over three years.* -
  • Results showed that TAVR patients had similar overall mortality rates but significantly fewer disabling strokes (0.6%) compared to surgery patients (2.9%), while TAVR also resulted in better valve performance.* -
  • Both treatment options had comparable low rates of valve reinterventions, but TAVR patients experienced higher rates of pacemaker implantation (21.0% vs. 7.1%).*
View Article and Find Full Text PDF

Background: The efficacy of direct oral anticoagulants (DOACs) in preventing ischemic and thromboembolic events may be suboptimal in atrial fibrillation (AF) patients with rheumatic mitral stenosis. However, their safety and effectiveness after mitral valve replacement (MVR) using bioprosthetic valves is unclear.

Objectives: This study sought to evaluate the safety and effectiveness of DOACs vs warfarin among patients with rheumatic heart disease (RHD)-associated AF after bioprosthetic MVR.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!